Thus, pharmacological treatment of CE may protect nigrostriatal neurons from MPTP-mediated toxicity and may pave a new pathway for BDNF, FGF2 and TrkB/Akt signaling axis as targets for the treatment of PD. This evidence concerns the gene AKT1 and Parkinson disease.